<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984370</url>
  </required_header>
  <id_info>
    <org_study_id>CKN-DASI-RYGB</org_study_id>
    <secondary_id>2019-001915-22</secondary_id>
    <nct_id>NCT03984370</nct_id>
  </id_info>
  <brief_title>Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass</brief_title>
  <official_title>Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is investigating the effect of a novel glucagon analogue administration
      in gastric bypass operated individuals, who are reactive hypoglycemic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Roux-En-Y gastric bypass (RYGB) has major health-promoting effects - reversing
      type-2-diabetes, improving dyslipidemia and inducing robust weight loss. However, several
      RYGB-individuals, post surgery, suffers from dumping syndrome and postprandial
      hyperinsulinemic hypoglycemia (PHH) due to the anatomical rearrangement of the
      gastro-intestinal system. Dasiglugaon (also known as (ZP4207) has shown great
      pharmacokinetic- and dynamic effects, compared to other glucagon analogues on the market,
      when administrated to hypoglycemic type-1-diabetics.

      Therefore we aim to examine the effects of two different doses of dasiglucagon on the
      postprandial nadir plasma glucose concentration in RYGB-operated individuals suffering from
      PHH by use of a mixed meal test (MMT).

      The study is designed as a double-blinded, randomised, 3-period, 3-treatment, crossover study
      comprising 3 separate treatment days in which participants will undergo an MMT along with one
      of the following double-blinded interventions:

        1. Subcutaneous (sc) placebo (saline) injection

        2. Sc injection with 80 μg dasiglucagon

        3. Sc injection with 200 μg dasiglucagon
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Actual">February 26, 2020</completion_date>
  <primary_completion_date type="Actual">February 26, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double-blinded, randomised, 3-period, 3-treatment, crossover study comprising 3 separate treatment days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nadir plasma glucose concentration within two hundred forty minutes after MMT</measure>
    <time_frame>Two hundred forty minutes</time_frame>
    <description>Nadir plasma glucose concentration within two hundred forty minutes after MMT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from dasiglucagon administration to recovery (first plasma glucose value above the fasting plasma glucose level</measure>
    <time_frame>Two hundred forty minutes</time_frame>
    <description>Time from dasiglucagon administration to recovery (first plasma glucose value above the fasting plasma glucose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in hypoglycaemia (plasma glucose concentration &lt;3.9 mmol/l) from study drug administration until 240 minutes</measure>
    <time_frame>Two hundred forty minutes</time_frame>
    <description>Time in hypoglycaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time below fasting plasma glucose level from study drug administration until two hundred forty minutes</measure>
    <time_frame>Two hundred forty minutes</time_frame>
    <description>Time below fasting plasma glucose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area 1: the area above the glucose curve and below the fasting level from the time of study drug administration until glucose values reach the fasting level.</measure>
    <time_frame>Two hundred forty minutes</time_frame>
    <description>Area 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area 2: the area below the glucose curve and above the fasting level from the time glucose values reach the fasting level until 240 minutes.</measure>
    <time_frame>Two hundred forty minutes</time_frame>
    <description>Area 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Edinburgh Hypoglycaemia Symptom Scale (EHSS) responses of the Edinburgh Hypoglycaemia Symptom Scale (EHSS) and early dumping symptoms based on</measure>
    <time_frame>t=zero to t=Two hundred forty minutes</time_frame>
    <description>likert scale one (absent) to seven (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Dumping Severity Score (DSS).</measure>
    <time_frame>t=zero to t=Two hundred forty minutes</time_frame>
    <description>likert scale, zero (absent) to three (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events and serious adverse events recorded during the meal test</measure>
    <time_frame>from t= minus thirty to t=Two hundred forty minutes</time_frame>
    <description>Frequency</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hyperinsulinemic Hypoglycemia</condition>
  <condition>Postprandial Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>80 ug of sc dasiglucagon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 ug of sc dasiglucagon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 ug of dasiglucagon in a 0.4 mL fluid (saline) is injected abdominal subcutaneous postprandial prior to hypoglycemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mL of sc saline (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.4 mL fluid (saline/placebo) is injected abdominal subcutaneous postprandial prior to hypoglycemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZP4207</intervention_name>
    <description>Abdominal SC administration</description>
    <arm_group_label>200 ug of sc dasiglucagon</arm_group_label>
    <arm_group_label>80 ug of sc dasiglucagon</arm_group_label>
    <other_name>Dasiglucagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>Abdominal SC administration</description>
    <arm_group_label>0.4 mL of sc saline (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented postprandial hypoglycaemia (&lt;3.9 mmol/l) by 6-day CGM or during a MMT

          -  Documented plasma glucose concentration excursions &gt;5.0 mmol/l by 6-day CGM or a MMT

          -  Haemoglobin levels for women &gt;7.3 mmol/l and for men &gt;8.3 mmol/l

          -  Ferritin &gt;10 μg/l

          -  Cobalamin &gt;150 pmol/l

          -  Fasting plasma glucose concentration within the range of 4.0-6.0 mmol/l CKN-DASI-RYGB
             protocol version 1.0 6

          -  Normal electrocardiogram (ECG)

          -  Negative urine human chorionic gonadotropin (hCG) (for fertile women)

        Exclusion Criteria:

          -  Treatment with medication(s) affecting insulin secretion or any antidiabetic drugs

          -  Treatment with antipsychotics

          -  Current participation in another clinical trial with administration of investigational
             drug.

          -  Previous exposure to dasiglucagon (otherwise known as ZP4207)

          -  History of liver disease that is expected to interfere with the anti-hypoglycaemic
             action of glucagon (e.g. liver failure or cirrhosis).

          -  Pregnancy

          -  Breastfeeding

          -  Any factors that, in the opinion of the site principal investigator or clinical
             protocol chair, would interfere with the safe completion of the study, including
             medical conditions that may require hospitalization during the trial or allergy to the
             ingredients in the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip M. Knop, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev-Gentofte Hospital, Center for Clinical Metabolic Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical Metabolic Research, Herlev-Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>March 28, 2020</last_update_submitted>
  <last_update_submitted_qc>March 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>MD, professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

